Drug Safety

Janet Pope
1 year 10 months ago
To remind us. Glory be! GLORIA a #RCT in elderly active #RA: MTX+10 mg daily #prednisolone which was better than MTX alone. But more infections and no comparison of inexpensive Rx such as adding #HCQ. Still debated as to benefit vs risk of this strategy @RheumNow #ACR23 @ACRheum https://t.co/slOmESbIOW
The RheumNow faculty reporters have been scouring the meeting for what they believe to be the best presentations from the first day at ACR 2023 in San Diego. From hundreds of online presentations, the poster floor and the plenary podium, here are some of the best abstracts from Sunday Nov. 12th. You can spot these on Twitter by looking for the (#ACRbest) hashtag.

Mike Putman EBRheum
1 year 10 months ago
Super interesting study re: impact of ORAL SURVEILLANCE on prescribing
Post safety report, JAK pts shifted younger w/lower comorbidities (esp CVD)
I know many have mixed feelings, but I believe in the risk & support this type of shift
@RheumNow Abstr0435 #ACR23 https://t.co/EBg9VOIbj1


Mike Putman EBRheum
1 year 10 months ago
No more underpowered long-term safety studies
We need a "SELECT-SURVEILLANCE" study to replicate ORAL-SURVEILLANCE & tell us if UPA has the same MACE/cancer risk as TOFA
Minus that, I plan to go 100% TOFA when it becomes generic in 2026
@RheumNow #ACR23 Abstr1326 https://t.co/LyQ1Q8qReO


Alessia Alunno
1 year 10 months ago
Real-life data about the PEXIVAS reduced-dose glucocorticoid regimen in #granulomatosis with polyangiitis and microscopic #polyangiitis (Abstract 0725 https://t.co/7x34Hr0OMP)
@TerrierBen
#ACR23
#ACRambassador https://t.co/D8UfZvXQCl


Meral K. El Ramahi, MD MeralElRamahiMD
1 year 10 months ago
ABS0524:
⭐️Benefit of Certolizumab (CZP) over standard non-biologic tx in reducing acute anterior uveitis (AAU) flares among high risk pts w/ axSpA
➡️active dz, HLAB27+, 2 or more AAU flares
⭐️CZP reduced AAU flare rate by 87%
#ACR23 @RheumNow
#ACRBest https://t.co/rW0N18agMO


TheDaoIndex KDAO2011
1 year 10 months ago
Are we tapering steroids too rapidly? Real world experience: steroid tapering in severe #AAV based on #PEXIVAS protocol noted higher rates of dz progression, relapse, ESRD, death. Risk greatest when creatinine > 300umol/L and w/RTX induction #Plenary1 #ACR23 Abst#0725 #ACrBest https://t.co/Rtv7vkzUUD


Aurelie Najm
1 year 10 months ago
Ph2a Nipocalumab: FcRn blocker
IV15mg/kg TNF IR RA 32 pts
Delta DASCRP -1 vs -0.5 PBO
ACR50 20% vs 0 PBO
DAS Remission 40% vs 16% Only in ACPA+ pts
SAEs 1 infusion related reaction
Not extremely convincing alone
Currently studied in combination w/ TNFi
@RheumNow #ACR23 ABST0839 https://t.co/6wTu2ellhN


David Liew drdavidliew
1 year 10 months ago
Lots of our patients taking CBD products, and they won’t always tell us…
but if you don’t ask, you’ll miss the drug-drug interaction that affects the meds we rely on.
#ACR23 @US_FDA session @RheumNow https://t.co/Q9UMJiTDkq


Eric Dein
1 year 10 months ago
Ab#498 Does DMARD for PsO and PsA decrease MACE?
#ACR23 @RheumNow
Retrospective database Israeli study.
PsO, PsA on MTX or bDMARD: lower MACE compared to health matched controled (HR 0.45-0.68, p<0.001)
Pts on topical Rx had marginally Increased MACE (HR 1.14, p <0.001) https://t.co/0uRgjzYbFp


Janet Pope
1 year 10 months ago
#Benefits of #hudroxychloroquine - reduced lipids, clots, CV events, infection AND now improved #fatty #liver #NAFLD….@RheumNow #ACR23 @ACRheum https://t.co/Y43JETY6F3

Mike Putman EBRheum
1 year 10 months ago
Important plenary re:reduced vs standard GC for AAV... IRL
PEXIVAS & recent guidelines supported low dose taper
Real world data w/severe dx? Increased risk of death & ESKD for REDUCED pts
Need full data but yikes...
@RheumNow #ACR23 #ACRBest https://t.co/3S23O9d1ok


Robert B Chao, MD
1 year 10 months ago
Interesting study on PEXIVAS reduced steroid use from today's plenary session!
Reduced steroid dose in GPA/MPA pts associated w/
INCREASED risk of death, ESKD, progression of dz
Even greater risk in pts with higher Cr lvls or RTX induction use
@RheumNow #ACR23 Abs#0725 #ACRbest https://t.co/frsOrANKhf
